Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) in India
The move strengthens GBL’s clinical-stage presence in the United States
The company shall process the change of name application with BSE Ltd. in due course
The company operates a chain of mid-sized multi-speciality hospitals
The inspection concluded with one minor observation in Form 483
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
Subscribe To Our Newsletter & Stay Updated
